Price Target Changes｜Credit Suisse Cut Snowflake to $415; HC Wainwright Cut Novavax to $207
Benzinga2022-03-03
- Piper Sandler cut the price target on Bright Health Group, Inc. from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.
- Needham cut C3.ai, Inc. price target from $103 to $26. C3.ai shares fell 0.7% to $22.50 in pre-market trading.
- SVB Leerink cut the price target on Gemini Therapeutics, Inc. from $10 to $2. Gemini Therapeutics shares gained 8.1% to close at $1.40 on Wednesday.
- Credit Suisse lowered the price target for Snowflake Inc. from $465 to $415. Snowflake shares fell 21.9% to $206.80 in pre-market trading.
- HC Wainwright & Co. lowered Novavax, Inc. price target from $294 to $207. Novavax shares fell 1% to $85.50 in pre-market trading.
- RBC Capital raised the price target on Biogen Inc. from $227 to $248. Biogen shares rose 0.9% to $209.59 in pre-market trading.
- Telsey Advisory Group reduced the price target for American Eagle Outfitters, Inc. from $31 to $25. American Eagle shares fell 7.2% to $19.80 in pre-market trading.
- Keybanc boosted ConocoPhillips price target from $98 to $106. ConocoPhillips shares rose 1.2% to $99.26 in pre-market trading.
- DA Davidson cut WW International, Inc. price target from $30 to $20. WW International shares fell 2.1% to $10.10 in pre-market trading.
- BMO Capital boosted Ball Corporation price target from $87 to $105. Ball shares rose 0.2% to $88.36 in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
